Cargando…

Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies

Human serum albumin nanoparticles (HSA-NPs) have been widely used as drug delivery systems. In most cases, HSA-NPs are formed by the method of desolvation in the presence of glutaraldehyde as a crosslinking agent. In the present study, we showed the possibility of crosslinking human serum albumin (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazhbayev, Yerkeblan, Mukashev, Olzhas, Burkeev, Meiram, Kreuter, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723891/
https://www.ncbi.nlm.nih.gov/pubmed/31409024
http://dx.doi.org/10.3390/pharmaceutics11080410
_version_ 1783448875954077696
author Tazhbayev, Yerkeblan
Mukashev, Olzhas
Burkeev, Meiram
Kreuter, Jörg
author_facet Tazhbayev, Yerkeblan
Mukashev, Olzhas
Burkeev, Meiram
Kreuter, Jörg
author_sort Tazhbayev, Yerkeblan
collection PubMed
description Human serum albumin nanoparticles (HSA-NPs) have been widely used as drug delivery systems. In most cases, HSA-NPs are formed by the method of desolvation in the presence of glutaraldehyde as a crosslinking agent. In the present study, we showed the possibility of crosslinking human serum albumin (HSA) molecules with natural agents, urea, and cysteine at the nanoparticle level under mild conditions (at room temperature of 20–25 °C). Optimal concentrations of the interacting components (HSA, urea, and cysteine) were found to produce nanoparticles with optimal physico-chemical parameters (particle size, polydispersity, zeta potential, yield, etc.) for application as drug carriers. We used hydroxyurea (HU), a simple organic compound currently used as a cancer chemotherapeutic agent. The results indicated sizes of 196 ± 5 nm and 288 ± 10 nm with a surface charge of −22 ± 3.4 mV and −17.4 ± 0.5 mV for HSA-NPs (20 mg/mL of HSA, 0.01 mg/mL of cysteine, and 10 mg/mL of urea) and HSA–HU-NPs (2 mg/mL of HU), respectively. The yield of the HSA–HU-NPs was ~93% with an encapsulation efficiency of ~77%. Thus, the particles created (immobilized with HU) were stable over time and able to prolong the effect of the drug.
format Online
Article
Text
id pubmed-6723891
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67238912019-09-10 Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies Tazhbayev, Yerkeblan Mukashev, Olzhas Burkeev, Meiram Kreuter, Jörg Pharmaceutics Article Human serum albumin nanoparticles (HSA-NPs) have been widely used as drug delivery systems. In most cases, HSA-NPs are formed by the method of desolvation in the presence of glutaraldehyde as a crosslinking agent. In the present study, we showed the possibility of crosslinking human serum albumin (HSA) molecules with natural agents, urea, and cysteine at the nanoparticle level under mild conditions (at room temperature of 20–25 °C). Optimal concentrations of the interacting components (HSA, urea, and cysteine) were found to produce nanoparticles with optimal physico-chemical parameters (particle size, polydispersity, zeta potential, yield, etc.) for application as drug carriers. We used hydroxyurea (HU), a simple organic compound currently used as a cancer chemotherapeutic agent. The results indicated sizes of 196 ± 5 nm and 288 ± 10 nm with a surface charge of −22 ± 3.4 mV and −17.4 ± 0.5 mV for HSA-NPs (20 mg/mL of HSA, 0.01 mg/mL of cysteine, and 10 mg/mL of urea) and HSA–HU-NPs (2 mg/mL of HU), respectively. The yield of the HSA–HU-NPs was ~93% with an encapsulation efficiency of ~77%. Thus, the particles created (immobilized with HU) were stable over time and able to prolong the effect of the drug. MDPI 2019-08-12 /pmc/articles/PMC6723891/ /pubmed/31409024 http://dx.doi.org/10.3390/pharmaceutics11080410 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tazhbayev, Yerkeblan
Mukashev, Olzhas
Burkeev, Meiram
Kreuter, Jörg
Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies
title Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies
title_full Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies
title_fullStr Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies
title_full_unstemmed Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies
title_short Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies
title_sort hydroxyurea-loaded albumin nanoparticles: preparation, characterization, and in vitro studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723891/
https://www.ncbi.nlm.nih.gov/pubmed/31409024
http://dx.doi.org/10.3390/pharmaceutics11080410
work_keys_str_mv AT tazhbayevyerkeblan hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies
AT mukashevolzhas hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies
AT burkeevmeiram hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies
AT kreuterjorg hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies